April 1, 2025 – German multinational pharmaceutical and biotechnology company Bayer announced plans to launch two new drugs targeting menopause symptoms and heart disease. These include
- Beyonttra (acoramidis) for treating a condition that causes heart failure.
- Elinzanetant for alleviating menopause-related hot flashes.
Both Beyonttra and Elinzanetant are expected to achieve annual peak sales of around US$ 1 billion. The expected product launches align with the company’s focus on expanding its women’s health portfolio and strengthening its position in the menopause treatment industry as well as the broader pharmaceutical sector.
Officials at the Bayern believe that both drugs have blockbuster potential. Elinzanetant will effectively help millions of women manage moderate to severe menopausal symptoms, including night sweats and hot flashes.
Beyonttra and Elinzanetant are expected to set new standards in menopause treatment and heart care segments. Rising popularity and adoption of Elinzanetant and similar drugs will play a key role in boosting growth of the menopause treatment industry.
According to Coherent Market Insights (CMI), the global menopause treatment industry is projected to experience a CAGR of 6.1% during the forecast period. Total industry size will likely reach around US$ 23 billion by 2032. This can be attributed to rising need for effective solutions to manage menopausal symptoms and new product launches and approvals, such as Bayer’s.
“Millions of women globally suffer from debilitating menopausal symptoms, yet effective treatment options remain limited. In response, companies like Bayer are stepping up as lifesavers by launching novel and effective drugs that offer much-need relief and improve quality of life,” says a senior analyst at CMI.”
Being a non-hormonal treatment option, Elinzanetant could be attractive to women seeking alternatives to hormonal replacement therapy. Its growing adoption will likely trigger growth in the menopause treatment industry in the coming years.
Bayer’s new menopause drug could intensify competition, especially against existing hormone replacement therapies as well as non-hormonal treatment. It will improve accessibility of menopause treatment, particularly in emerging markets where menopause care is still underdeveloped.
Similar to Bayer, other pharmaceutical companies might follow suit by developing and launching advanced non-hormonal medications. This can further expand the global menopause treatment industry.
Sources:
News Outlet: Reuters
